PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Medication, Amphetamine, Cii, Firstcall, Lisdexamfetamine Dimesylate, Lse, Median Time, Medication, Nasdaq, Pharmacokinetic Profile, Plasma Concentration, Ppi, Prilosec, Prilosec Otc, Prnewswire, Proton Pump Inhibitor, Shire, Shp, Vyvanse
PHILADELPHIA – May 22, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. read more
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Medication, Amphetamine, Cii, Lse, Maximum, Median Time, Medication, Nasdaq, Pharmacokinetics, Philadelphia, Plasma Concentration, Ppi, Prilosec, Prilosec Otc, Proton Pump Inhibitor, Shp
